Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Knockdown of ISG15 had minimal effects on tumor growth but did decrease tumor lymphangiogenesis and lymphatic metastasis of LN1-1 cells.
|
30765861 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Knocking down ISG15 with shRNA inhibited the xenografted tumor growth.
|
31195151 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, ISG15 knockdown alone significantly decreased the number of tumor-infiltrating regulatory T cells (Tregs) compared to wild type tumors treated with anti-PD-1 antibody.
|
31709456 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Enhanced protein level of ISG15 promoted cellular malignant phenotypes including proliferation, migration, invasion and tumor formation in vivo.
|
29555370 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The ubiquitin-like modifier interferon-stimulated gene 15 (ISG15) is implicated in both oncogenic and tumor suppressive programs.
|
27980214 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The functions of free and conjugated ISG15 are ambiguous in tumorigenesis owing to its roles as an oncogene and a tumour suppressor gene.
|
28285335 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ISG15 mRNA expression was quantified by qRT-PCR in 36 tumor and adjacent non-tumor tissues.
|
27626177 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings establish a novel feedback circuit between p53 and ISG15-conjugating system for positive regulation of the tumour suppressive function of p53 under DNA damage conditions.
|
27545325 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results provide more insight into the immunomodulatory properties of ISG15 and its potential to serve as an effective immune adjuvant in a therapeutic tumor or infectious disease setting.
|
26122932 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Krüppel-like factor 9 (KLF9) is a haploinsufficient tumor suppressor in the ApcMin/+ mouse colon by suppressing expression of ISG15, an apoptosis-inhibiting cytokine.
|
26210742 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ISG15 was preferentially and highly expressed by TAM present in primary PDAC tumors resected from patients.
|
25368022 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We propose that loss of p53 function and subsequent ARF induction creates a selective pressure to inactivate ARF and propose that tumors harboring coinactivation of ARF and p53 would benefit from therapies targeted against STAT1 and ISG15 activation.
|
24726362 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Knowing down ISG15 with SiRNA inhibited the xenografted tumor growth and prolonged the lifespan of tumor-bearing mice.
|
25238261 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Given the emerging relationship between malignant transformation and ISG15, we sought to examine the expression pattern of this gene in tumor biopsies of oral squamous cell carcinoma (OSCC) tissues collected from Indian patients.
|
23621203 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Because the cellular architecture is conserved and the ISG15 pathway is constitutively activated in tumor cells of different lineages, it is reasonable to assume that our observations in breast cancer must hold true for many other tumors.
|
22185919 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings establish ISG15 as a tumor suppressor via its conjugation to ΔNp63α and provide a molecular rationale for therapeutic use of doxorubicin against ΔNp63α-mediated cancers.
|
22706304 |
2012 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we show (i) that the ubiquitin-like modifier, interferon-stimulated gene 15 (ISG15), and most enzymes involved in ISG15 conjugation were upregulated in tumor samples versus in non-malignant tissues of PCa patients and (ii) that the expression of these components significantly differed between tumors in patients treated with and without androgen ablation.
|
19430494 |
2009 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
First, short hairpin RNA-mediated knockdown of either ISG15 or UbcH8 (major E2 for ISG15) in breast cancer ZR-75-1 cells decreased CPT sensitivity, suggesting that ISG15 overexpression in tumors could be a factor affecting intrinsic CPT sensitivity in tumor cells.
|
18566215 |
2008 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we review evidence of a role for ISG15 as an endogenous tumor suppressor that, when dysregulated in malignant cells, can be subverted to promote oncogenesis.
|
17097911 |
2006 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Most importantly, strong cytoplasmic expression of ISG15 was detected by immunohistochemistry in the original tumor specimen from which the melanoma cell lines under investigation were derived.
|
12067988 |
2002 |